Regarding the choice of pharmacological therapy, this should take into consideration the mechanisms of insulin resistance, secretory capacity of the pancreas, metabolic disorders involved, and the complications of DM2 present (American Diabetes Association [ADA], 2018). Here, INS is linked to myotonic dystrophy type 2.